A Phase III, Non-Inferiority, Randomized, Double-Blind, Parallel-Group, Multicentre, Single-Dose, Comparative Clinical Study of Lactase Eurofarma (Test Drug) and Lactaid® (Comparative Drug), Assessing the Efficacy and Safety in the Treatment of Patients With Lactose Intolerance (Hypolactasia)
| Registry | NCT01145339, acronym EF099 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional; randomized, parallel, masking: single, treatment |
| Enrollment | 140 (Actual) |
| Sponsor | Eurofarma Laboratorios S.A. (Industry) |
| Conditions | Hypolactasia |
| Interventions | Lactase (Drug) |
| Dates | start 2011-07-01, primary completion 2011-11-01, completion 2012-03-01, first posted 2010-06-16, last updated 2012-06-26 |
| Locations | 7 sites in Brazil |
Related Papers Related Patents Related Grants Related Experts
All trials for Hypolactasia All trials of Lactase
The study primary objective is to compare the clinical efficacy of two formulations in the supportive treatment of lactose intolerance.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Lactase EUF | Experimental | Drug: Lactase | 1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g). |
| Lactase Ref | Active comparator | Drug: Lactase | 1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g). |
Sex: All, ages: 18 Years to 60 Years
Inclusion Criteria: 1. The patient should be a male or female, aged between 18 and 60 years old; 2. Have a medical history consistent with lactose intolerance, confirmed by the test of hydrogen in the expired air; 3. The female patients should agree to use birth control methods during the study participation; 4. To be able to meet the study instructions and all the visits required; 5. To give a free consent to participate in the study and sign the informed consent form (ICF). Exclusion Criteria: 1. Smoking; 2. Secondary hypolactasia; 3. Gastrointestinal inflammatories diseases - present diverticular disease, diabetic gastropathy or neoplasias; 4. Colonoscopy or colon cleaning procedure 4 weeks before the start of study 5. Latrogenic: unnoticed intake of laxatives in over-the-counter drugs or alternative medicine, intake of cereal bran or probiotics; 6. Diagnosis of HIV, immunodepression of any origin, or cancer under treatment. 7. Diagnosis of other comorbidity that, at the investigator's discretion, may compromise the study participation (e.g., systemic infection during the study or use of antibiotics in the last 4 weeks, diabetes mellitus, uncontrolled hypertension or renal failure), 8. Hypersensitivity or previous laboratory or clinical adverse event related to the use of lactase or any of the components of the formulations used in the study; 9. Incapacity to understand and complete the study questionnaires, including the questions that require the use of the Visual Analogue Scale and ICF; 10. Pregnancy or lactation; 11. Use of alcohol, exceeding 3 doses daily; 12. Participation in another clinical study on the last 12 months; 13. Patient having some chronic pulmonary disease that, in the investigator's opinion, may harm or interfere with the expired hydrogen test (e.g., cystic fibrosis).
| Facility | City | Country | Status |
|---|---|---|---|
| Instituto Goiano de Gastroenterologia | Goiânia, Goiás | Brazil | |
| Instituto Alfa de Gastroenterologia | Belo Horizonte, Minas Gerais | Brazil | |
| Hospital Nossa Senhora das Graças | Curitiba, Paraná | Brazil | |
| Hospital São Lucas | Porto Alegre, Rio Grande do Sul | Brazil | |
| Hospital Mãe de Deus | Porto Alegre, Rio Grande do Sul | Brazil | |
| Faculdade de Medicina do ABC | Santo André, São Paulo | Brazil | |
| Hospital São Paulo / UNIFESP | São Paulo, São Paulo | Brazil |